A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in
combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic
melanoma and pancreatic ductal adenocarcinoma (PDAC)